Related references
Note: Only part of the references are listed.Human Papillomavirus Genotype Replacement: Still Too Early to Tell?
Irene Man et al.
JOURNAL OF INFECTIOUS DISEASES (2021)
Economic assessments of the burden of congenital cytomegalovirus infection and the cost-effectiveness of prevention strategies
Scott D. Grosse et al.
SEMINARS IN PERINATOLOGY (2021)
Recombinant Zoster Vaccine (Shingrix): Real-World Effectiveness in the First 2 Years Post-Licensure
Hector S. Izurieta et al.
CLINICAL INFECTIOUS DISEASES (2021)
Early examination of real-world uptake and second-dose completion of recombinant zoster vaccine in the United States from October 2017 to September 2019
Brandon J. Patterson et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2021)
Seasonal trivalent inactivated influenza vaccine with topical imiquimod in immunocompromised patients: A randomized controlled trial
Matteo Mombelli et al.
JOURNAL OF INFECTION (2021)
Effectiveness and Cost-Effectiveness of Human Papillomavirus Vaccination Through Age 45 Years in the United States
Jean-Francois Laprise et al.
ANNALS OF INTERNAL MEDICINE (2020)
Cost-effectiveness of continuing pneumococcal conjugate vaccination at age 65 in the context of indirect effects from the childhood immunization program
Charles Stoecker et al.
VACCINE (2020)
Final analysis of a 14-year long-term follow-up study of the effectiveness and immunogenicity of the quadrivalent human papillomavirus vaccine in women from four nordic countries
Susanne K. Kjaer et al.
ECLINICALMEDICINE (2020)
Long-term immunogenicity, effectiveness, and safety of nine-valent human papillomavirus vaccine in girls and boys 9 to 15 years of age: Interim analysis after 8 years of follow-up
Sven-Eric Olsson et al.
PAPILLOMAVIRUS RESEARCH (2020)
Cost-effectiveness of HPV vaccination for adults through age 45 years in the United States: Estimates from a simplified transmission model
Harrell W. Chesson et al.
VACCINE (2020)
A Cost-Effectiveness Analysis of Vaccination for Prevention of Herpes Zoster and Related Complications: Input for National Recommendations
Lisa A. Prosser et al.
ANNALS OF INTERNAL MEDICINE (2019)
Making sense of differences in pneumococcal serotype replacement
Joseph A. Lewnard et al.
LANCET INFECTIOUS DISEASES (2019)
Pneumococcal lineages associated with serotype replacement and antibiotic resistance in childhood invasive pneumococcal disease in the post-PCV13 era: an international whole-genome sequencing study
Stephanie W. Lo et al.
LANCET INFECTIOUS DISEASES (2019)
Human Papillomavirus Vaccination for Adults: Updated Recommendations of the Advisory Committee on Immunization Practices
Elissa Meites et al.
MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2019)
Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Adults Aged ≥65 Years: Updated Recommendations of the Advisory Committee on Immunization Practices
Almea Matanock et al.
MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2019)
Cost-effectiveness of adult vaccinations: A systematic review
Andrew J. Leidner et al.
VACCINE (2019)
Ten Years of Human Papillomavirus Vaccination in the United States
Lauri E. Markowitz et al.
ACADEMIC PEDIATRICS (2018)
Economic Analysis of Vaccination Programs
Josephine Mauskopf et al.
VALUE IN HEALTH (2018)
Updated Framework for Development of Evidence-Based Recommendations by the Advisory Committee on Immunization Practices
Grace Lee et al.
MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2018)
A 12-Year Follow-up on the Long-Term Effectiveness of the Quadrivalent Human Papillomavirus Vaccine in 4 Nordic Countries
Susanne K. Kjaer et al.
CLINICAL INFECTIOUS DISEASES (2018)
Optimising the introduction of multiple childhood vaccines in Japan: A model proposing the introduction sequence achieving the highest health gains
Baudouin Standaert et al.
HEALTH POLICY (2017)
Age of Acquiring Causal Human Papillomavirus (HPV) Infections: Leveraging Simulation Models to Explore the Natural History of HPV-induced Cervical Cancer
Emily A. Burger et al.
CLINICAL INFECTIOUS DISEASES (2017)
Methods for Health Economic Evaluation of Vaccines and Immunization Decision Frameworks: A Consensus Framework from a European Vaccine Economics Community
Bernhard Ultsch et al.
PHARMACOECONOMICS (2016)
Incremental Cost-Effectiveness of 13-valent Pneumococcal Conjugate Vaccine for Adults Age 50 Years and Older in the United States
Charles Stoecker et al.
JOURNAL OF GENERAL INTERNAL MEDICINE (2016)
Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older
A. L. Cunningham et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
The cost-effectiveness of pneumococcal vaccination in healthy adults over 50: An exploration of influential factors for Belgium
Adriaan Blommaert et al.
VACCINE (2016)
Population-level impact, herd immunity, and elimination after human papillomavirus vaccination: a systematic review and meta-analysis of predictions from transmission-dynamic models
Marc Brisson et al.
LANCET PUBLIC HEALTH (2016)
Efficacy of an Adjuvanted Herpes Zoster Subunit Vaccine in Older Adults
Himal Lal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
HPV catch-up vaccination of young women: a systematic review and meta-analysis
Elisabeth Couto et al.
BMC PUBLIC HEALTH (2014)
Economic Evaluation of the Routine Childhood Immunization Program in the United States, 2009
Fangjun Zhou et al.
PEDIATRICS (2014)
Questionnaire to Assess Relevance and Credibility of Modeling Studies for Informing Health Care Decision Making: An ISPOR-AMCP-NPC Good Practice Task Force Report
J. Jaime Caro et al.
VALUE IN HEALTH (2014)
Sustained efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine Final analysis of a long-term follow-up study up to 9.4 years post-vaccination
Paulo S. Naud et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2014)
Cost-effectiveness of administering 13-valent pneumococcal conjugate vaccine in addition to 23-valent pneumococcal polysaccharide vaccine to adults with immunocompromising conditions
Bo-Hyun Cho et al.
VACCINE (2013)
The cost-effectiveness of a 13-valent pneumococcal conjugate vaccination for infants in England
Albert Jan van Hoek et al.
VACCINE (2012)
Dynamic Transmission Modeling: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force-5
Richard Pitman et al.
VALUE IN HEALTH (2012)
Serotype replacement in disease after pneumococcal vaccination
Daniel M. Weinberger et al.
LANCET (2011)
Update on the success of the pneumococcal conjugate vaccine
J. D. Kellner
PAEDIATRICS & CHILD HEALTH (2011)
Understanding differences in predictions of HPV vaccine effectiveness: A comparative model-based analysis
Nicolas Van de Velde et al.
VACCINE (2010)
A Pooled Analysis of Continued Prophylactic Efficacy of Quadrivalent Human Papillomavirus (Types 6/11/16/18) Vaccine against High-grade Cervical and External Genital Lesions
Susanne K. Kjaer et al.
CANCER PREVENTION RESEARCH (2009)
Incorporating Herd Immunity Effects into Cohort Models of Vaccine Cost-Effectiveness
Chris T. Bauch et al.
MEDICAL DECISION MAKING (2009)
Longer term efficacy of a prophylactic monovalent human papillomavirus type 16 vaccine
Ali Rowhani-Rahbar et al.
VACCINE (2009)
Dynamic modelling of infectious diseases - An application to the economic evaluation of influenza vaccination
Roberto Pradas-Velasco et al.
PHARMACOECONOMICS (2008)
Cost-effectiveness analyses of vaccination programmes - A focused review of modelling approaches
Sun-Young Kim et al.
PHARMACOECONOMICS (2008)
Incidence of pneumococcal disease due to non-pneumococcal conjugate vaccine (PCV7) serotypes in the united states during the era of widespread PCV7 vaccination, 1998-2004
Lauri A. Hicks et al.
JOURNAL OF INFECTIOUS DISEASES (2007)
Good research practices for cost-effectiveness analysis alongside clinical trials: The ISPOR RCT-CEA task force report
S Ramsey et al.
VALUE IN HEALTH (2005)
Economic evaluation of vaccination programs: The impact of herd-immunity
M Brisson et al.
MEDICAL DECISION MAKING (2003)
Share Paper
